{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:29Z","timestamp":1753891949712,"version":"3.41.2"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00843","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T14:02:07Z","timestamp":1591365727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Hypertensive Retinopathy Secondary to Anlotinib Treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaohua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)","volume":"118","author":"Han","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.disamonth.2016.10.002","article-title":"Review of hypertensive retinopathy","volume":"63","author":"Harjasouliha","year":"2017","journal-title":"Dis. Mon."},{"key":"B3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5830\/cvja-2014-045","article-title":"Hypertensive retinopathy and its association with cardiovascular, renal and cerebrovascular morbidity in Congolese patients","volume":"25","author":"Kabedi","year":"2014","journal-title":"Cardiovasc. J. Afr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/hypertensionaha.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.2147\/ott.s205674","article-title":"The efficacy and safety of anlotinib treatment for advanced lung cancer","volume":"12","author":"Shao","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2147\/ott.s235349","article-title":"Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced\/Metastatic Soft Tissue Sarcoma","volume":"13","author":"Wang","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1634\/theoncologist.2018-0839","article-title":"Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial","volume":"24","author":"Zhou","year":"2019","journal-title":"Oncologist"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T14:02:08Z","timestamp":1591365728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":11,"alternative-id":["10.3389\/fphar.2020.00843"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00843","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"article-number":"843"}}